Literature DB >> 25052881

Feasibility of providing interventions for injection drug users in pharmacy settings: a case study among San Francisco pharmacists.

Valerie J Rose1, Alexandra Lutnick, Alex H Kral.   

Abstract

In addition to syringe exchange programs, pharmacies are important venues where injection drug users (IDUs) can access non-prescription syringes and other prevention interventions. This study assessed the feasibility of providing a range of interventions for IDUs in pharmacy settings. Semi-structured qualitative interviews were conducted with 23 participants (policy makers, owner/managers, dispensing pharmacists, and pharmacy staff) from independent and chain/retail pharmacies in San Francisco, California, USA. The highest level of support was for a coupon syringe program and educational materials. Several overarching themes illustrate challenges to implementing pharmacy-based preventive interventions: time, space, sufficient staff, pharmacist training, legal considerations, pharmacist attitudes toward IDUs, and cost and reimbursement issues. This study provides concrete examples of the types of preventive services that pharmacists support and consider feasible, and illustrates that pharmacists welcome the opportunity to broaden their role as critical partners in public health matters related to injection drug use.

Entities:  

Keywords:  harm reduction; injection drug use; non-prescription syringe sales; pharmacy; policy; public Health

Mesh:

Substances:

Year:  2014        PMID: 25052881      PMCID: PMC4112371          DOI: 10.1080/02791072.2014.921745

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  34 in total

1.  Effect of vaccination by community pharmacists among adult prescription recipients.

Authors:  J D Grabenstein; H A Guess; A G Hartzema; G G Koch; T R Konrad
Journal:  Med Care       Date:  2001-04       Impact factor: 2.983

2.  Trends in HIV seroprevalence and risk among gay and bisexual men who inject drugs in San Francisco, 1988 to 2000.

Authors:  R N Bluthenthal; A H Kral; L Gee; J Lorvick; L Moore; K Seal; B R Edlin
Journal:  J Acquir Immune Defic Syndr       Date:  2001-11-01       Impact factor: 3.731

3.  Impact of pharmacy-based syringe access on injection practices among injecting drug users in Minnesota, 1998 to 1999.

Authors:  N U Cotten-Oldenburg; P Carr; J M DeBoer; E K Collison; G Novotny
Journal:  J Acquir Immune Defic Syndr       Date:  2001-06-01       Impact factor: 3.731

4.  Two- to sixfold decreased odds of HIV risk behavior associated with use of syringe exchange.

Authors:  David R Gibson; Richard Brand; Kim Anderson; James G Kahn; Daniel Perales; Joseph Guydish
Journal:  J Acquir Immune Defic Syndr       Date:  2002-10-01       Impact factor: 3.731

5.  Injection risk behaviors among clients of syringe exchange programs with different syringe dispensation policies.

Authors:  Alex H Kral; Rachel Anderson; Neil M Flynn; Ricky N Bluthenthal
Journal:  J Acquir Immune Defic Syndr       Date:  2004-10-01       Impact factor: 3.731

6.  Pharmacy syringe purchase test of nonprescription syringe sales in San Francisco and Los Angeles in 2010.

Authors:  Alexandra Lutnick; Erin Cooper; Chaka Dodson; Ricky Bluthenthal; Alex H Kral
Journal:  J Urban Health       Date:  2013-04       Impact factor: 3.671

7.  Health care need and utilization: a preliminary comparison of injection drug users, other illicit drug users, and nonusers.

Authors:  D D Chitwood; D C McBride; M T French; M Comerford
Journal:  Subst Use Misuse       Date:  1999 Mar-Apr       Impact factor: 2.164

8.  Pharmacy access to syringes among injecting drug users: follow-up findings from Hartford, Connecticut.

Authors:  M Singer; H A Baer; G Scott; S Horowitz; B Weinstein
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

9.  Barriers to enrollment in drug abuse treatment and suggestions for reducing them: opinions of drug injecting street outreach clients and other system stakeholders.

Authors:  Philip W Appel; Aletha A Ellison; Hadley K Jansky; Rivka Oldak
Journal:  Am J Drug Alcohol Abuse       Date:  2004       Impact factor: 3.829

10.  Health services utilization by injection drug users participating in a needle exchange program.

Authors:  Elise D Riley; Albert W Wu; Benjamin Junge; Melissa Marx; Steffanie A Strathdee; David Vlahov
Journal:  Am J Drug Alcohol Abuse       Date:  2002       Impact factor: 3.829

View more
  9 in total

1.  Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.

Authors:  Amy Bachyrycz; Shikhar Shrestha; Barry E Bleske; Dale Tinker; Ludmila N Bakhireva
Journal:  Subst Abus       Date:  2016-05-10       Impact factor: 3.716

2.  Self-reported participation in voluntary nonprescription syringe sales in California's Central Valley.

Authors:  Robin A Pollini
Journal:  J Am Pharm Assoc (2003)       Date:  2017-08-12

3.  Reality and feasibility for pharmacy-delivered services for people who inject drugs in Xichang, China: Comparisons between pharmacy staff and people who inject drugs.

Authors:  Yi Yang; Carl Latkin; Rongsheng Luan; Cui Yang
Journal:  Int J Drug Policy       Date:  2015-06-09

4.  Neighborhood-Level and Spatial Characteristics Associated with Lay Naloxone Reversal Events and Opioid Overdose Deaths.

Authors:  Christopher Rowe; Glenn-Milo Santos; Eric Vittinghoff; Eliza Wheeler; Peter Davidson; Philip O Coffin
Journal:  J Urban Health       Date:  2016-02       Impact factor: 3.671

5.  A cross-sectional study of the feasibility of pharmacy-delivered harm reduction services among people who inject drugs in Xichang, China.

Authors:  Yi Yang; Carl A Latkin; Rongsheng Luan; Cui Yang
Journal:  BMC Public Health       Date:  2015-09-14       Impact factor: 3.295

6.  Acceptability and feasibility of a pharmacist-led HIV pre-exposure prophylaxis (PrEP) program in the Midwestern United States.

Authors:  Joshua P Havens; Kimberly K Scarsi; Harlan Sayles; Donald G Klepser; Susan Swindells; Sara H Bares
Journal:  Open Forum Infect Dis       Date:  2019-10-01       Impact factor: 3.835

7.  The status of naloxone in community pharmacies across Canada.

Authors:  Randy So; Yazid Al Hamarneh; Mark Barnes; Michael A Beazely; Michael Boivin; Julie Laroche; Harsit Patel; Aaron Sihota; Tim Smith; Ross T Tsuyuki
Journal:  Can Pharm J (Ott)       Date:  2020-09-21

8.  Community pharmacist engagement in HIV and HCV prevention: Current practices and potential for service uptake.

Authors:  KariLynn Dowling-McClay; Stephanie M Mathis; Nicholas Hagemeier
Journal:  Explor Res Clin Soc Pharm       Date:  2021-10-28

9.  Orienting patients to greater opioid safety: models of community pharmacy-based naloxone.

Authors:  Traci C Green; Emily F Dauria; Jeffrey Bratberg; Corey S Davis; Alexander Y Walley
Journal:  Harm Reduct J       Date:  2015-08-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.